Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Dietrich Hueppe"'
Autor:
Christoph Boesecke, Jenny Bischoff, Jürgen K. Rockstroh, Stefan Christensen, Axel Baumgarten, Patrick Ingiliz, Florian Berger, Thomas A. Lutz, Stefan Mauss, Julian Schulze zur Wiesch, Karl-Georg Simon, Carl Knud Schewe, Dietrich Hueppe
Publikováno v:
Journal of Clinical Gastroenterology. 54:192-199
International guidelines recommend prioritized treatment initiation in hepatitis C virus (HCV)-infected patients with advanced liver disease. We aimed to evaluate whether the widespread usage of direct acting antivirals (DAAs) has led to a decrease i
Autor:
Juergen K. Rockstroh, Axel Baumgarten, Knud Schewe, Karl-Georg Simon, Stefan Mauss, P. Ingiliz, Christoph Boesecke, Thomas A. Lutz, Stefan Christensen, Dietrich Hueppe, Julian Schulze zur Wiesch, Malte H. Wehmeyer
Publikováno v:
Clinical Infectious Diseases. 71:1248-1254
Background Micro-elimination of the hepatitis C virus (HCV) includes treatment in populations at risk of ongoing HCV transmission, such as men who have sex with men (MSM) or people who inject drugs (PWID). We analyzed the HCV reinfection incidence ra
Autor:
Kurt Gruengreiff, H Pfeiffer-Vornkahl, Dietrich Hueppe, Petra Sandow, Joerg Goelz, Heiner Wedemeyer, Thomas A. Lutz, Jens Reimer, Stefan Christensen, Ulrich Alshuth, Michael P. Manns
Publikováno v:
Liver International. 37:1468-1475
Background & Aims There are few large-scale, prospective studies comparing liver-associated events in treated and untreated patients with CHC managed in routine clinical practice. Methods Patients with CHC were prospectively enrolled in a non-interve
Autor:
Christoph Sarrazin, Jörg Timm, Axel Baumgarten, Karl-Georg Simon, Patrick Ingiliz, Juergen K. Rockstroh, N. Luebke, Dietrich Hueppe, J von Felden, Johannes Vermehren, Knud Schewe, M. Daeumer, HW Busch, S. Christensen, Christoph Boesecke, J Schulze zur Wiesch, Stefan Mauss, Thomas A. Lutz
Publikováno v:
Alimentary pharmacologytherapeutics. 47(9)
Background Twelve weeks of the pangenotypic direct-acting antiviral (DAA) combination sofosbuvir/velpatasvir (SOF/VEL) was highly efficient in patients with hepatitis C virus (HCV) genotype 3 (GT3) infection in the ASTRAL-3 approval study. However, p
Autor:
Karl Georg Simon, Guenther Schmutz, Stefan Mauss, HW Busch, Knud Schewe, Florian Berger, Juergen K. Rockstroh, Axel Baumgarten, Julian Schulze zur Wiesch, Torben Kimhofer, Malte H. Wehmeyer, Christoph Boesecke, Thomas A. Lutz, Patrick Ingiliz, Stefan Christensen, Dietrich Hueppe
Publikováno v:
Journal of medical virology. 90(2)
There are limited data regarding the real world effectiveness of direct acting antivirals (DAA) for the therapy of chronic genotype 3 hepatitis C virus (HCV) infection. All HCV genotype 3 infected patients from the German hepatitis C cohort (GECCO),
Autor:
Dietrich Hueppe, Juergen K. Rockstroh, Axel Baumgarten, Knud Schewe, Thomas A. Lutz, Stefan Mauss, Florian Berger, Stefan Christensen, Malte H. Wehmeyer, Patrick Ingiliz, Karl Georg Simon
Publikováno v:
Antiviral therapy. 21(1)
Background HCV has complex interactions with human lipid metabolism leading to down regulation of cholesterol levels. Interferon (IFN) therapy has been shown to decrease cholesterol even further. With the availability of second-generation direct-acti
Autor:
Thomas A. Lutz, Patrick Ingiliz, Axel Baumgarten, Knud Schewe, Florian Berger, Stefan Mauss, S. Christensen, Günther Schmutz, Malte H. Wehmeyer, Christoph Boesecke, Dietrich Hueppe, HW Busch, Karl-Georg Simon, Julian Schulze zur Wiesch, Torben Kimhofer, Jürgen K. Rockstroh
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 63(10)
Background Shortening the duration of treatment with HCV direct-acting antivirals (DAAs) leads to substantial cost reductions. According to the label, sofosbuvir and ledipasvir can be prescribed for 8 weeks (SL8) in noncirrhotic women or men with HCV
Autor:
Daniel Grimm, Tim Zimmermann, Dietrich Hueppe, Peter Buggisch, Peter R. Galle, H Pfeiffer-Vornkahl, Ulrich Alshuth, Stefan Mauss
Publikováno v:
Web of Science
Background & Aims: Smoking has multiple effects on factors influencing hepatitis C and antiviral therapy, including lipid metabolism, fibrosis, platelet count and adherence aspects. The aim of this analysis was to determine the impact of smoking on h
Autor:
Stefan Christensen, T. Lutz, K. Simon, Christoph Boesecke, Florian Berger, P. Ingiliz, Knud Schewe, Juergen K. Rockstroh, Dietrich Hueppe, Stefan Mauss, Axel Baumgarten
Publikováno v:
Journal of Hepatology. 66:S739-S740
Autor:
A. Herrmann, Gerlinde Teuber, Thomas Witthoeft, Christine John, Alex Baumgarten, B. Moeller, Ralph Link, Karl-Georg Simon, Renate Heyne, Dietrich Hueppe, Nektarios Dikopoulos, Joerg Goelz, Maria Spelter, S. Wollschlaeger, Stefan Mauss
Publikováno v:
Journal of Viral Hepatitis. 18:e81-e90
The likelihood of a sustained virological response (SVR) is the most important factor for physicians and patients in the decision to initiate and continue therapy for chronic hepatitis C (CHC) infection. This study identified predictive factors for S